[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY31758A - Forma cristalina anhidra de maleato de orvepitant - Google Patents

Forma cristalina anhidra de maleato de orvepitant

Info

Publication number
UY31758A
UY31758A UY0001031758A UY31758A UY31758A UY 31758 A UY31758 A UY 31758A UY 0001031758 A UY0001031758 A UY 0001031758A UY 31758 A UY31758 A UY 31758A UY 31758 A UY31758 A UY 31758A
Authority
UY
Uruguay
Prior art keywords
anhydra
crystal form
orvepitant maleate
maleate
orvepitant
Prior art date
Application number
UY0001031758A
Other languages
English (en)
Inventor
Beato Stefania
Sartor Franco
Ian Philip Steeples
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY31758A publication Critical patent/UY31758A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

La invención se refiere a maleato de orvepitant cristalino anhidro (Forma 1), a formulaciones farmacéuticas que lo comprenden, a su uso en terapia y a procesos para prepararlo.
UY0001031758A 2008-04-11 2009-04-13 Forma cristalina anhidra de maleato de orvepitant UY31758A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0806652.4A GB0806652D0 (en) 2008-04-11 2008-04-11 Anhydrous crystal form of orvepitant maleate

Publications (1)

Publication Number Publication Date
UY31758A true UY31758A (es) 2009-11-10

Family

ID=39433527

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031758A UY31758A (es) 2008-04-11 2009-04-13 Forma cristalina anhidra de maleato de orvepitant

Country Status (27)

Country Link
US (1) US8309553B2 (es)
EP (1) EP2297152B1 (es)
JP (2) JP5875863B2 (es)
KR (1) KR20110002090A (es)
CN (1) CN102066376B (es)
AR (1) AR071311A1 (es)
AU (1) AU2009235440B2 (es)
BR (1) BRPI0911678B8 (es)
CA (1) CA2721119C (es)
CL (1) CL2009000876A1 (es)
CY (1) CY1115961T1 (es)
DK (1) DK2297152T3 (es)
EA (1) EA017082B1 (es)
ES (1) ES2529295T3 (es)
GB (1) GB0806652D0 (es)
HR (1) HRP20141196T1 (es)
IL (1) IL208597A0 (es)
MX (1) MX2010011152A (es)
PE (1) PE20091839A1 (es)
PL (1) PL2297152T3 (es)
PT (1) PT2297152E (es)
RS (1) RS53732B1 (es)
SI (1) SI2297152T1 (es)
TW (1) TW201002714A (es)
UY (1) UY31758A (es)
WO (1) WO2009124996A1 (es)
ZA (1) ZA201007120B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009056151A1 (en) * 2007-10-30 2009-05-07 Elekta Ab (Publ) Radiotherapy apparatus
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
CN104703603A (zh) 2012-10-11 2015-06-10 尼尔医疗有限公司 新用途
AU2016384267B2 (en) * 2016-01-08 2022-02-03 Nerre Therapeutics Limited Orvepitant for the treatment of chronic cough
BR112019021125A2 (pt) 2017-04-10 2020-05-12 Chase Therapeutics Corporation Combinação de antagonista de nk1 e método para tratamento de sinucleinopatias
EA202090180A1 (ru) 2017-06-30 2020-05-26 Чейс Терапьютикс Корпорейшн Композиции nk1-антагониста и способы лечения депрессии
IL272697B2 (en) 2017-08-18 2023-12-01 Adastra Pharmaceuticals Inc A polymorphic form of TG02
WO2021198255A1 (en) 2020-04-03 2021-10-07 Nerre Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
MX2022014901A (es) 2020-06-02 2023-01-18 Nerre Therapeutics Ltd Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
AU2007253704A1 (en) 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
WO2009059326A2 (en) * 2007-11-02 2009-05-07 Entegris, Inc. Integral face seal
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate

Also Published As

Publication number Publication date
BRPI0911678B1 (pt) 2021-03-02
CN102066376B (zh) 2014-01-01
CL2009000876A1 (es) 2010-05-14
JP2011516532A (ja) 2011-05-26
CA2721119A1 (en) 2009-10-15
TW201002714A (en) 2010-01-16
EA201071183A1 (ru) 2011-06-30
CA2721119C (en) 2016-04-05
KR20110002090A (ko) 2011-01-06
ES2529295T3 (es) 2015-02-18
DK2297152T3 (da) 2015-01-26
EA017082B1 (ru) 2012-09-28
PT2297152E (pt) 2015-02-16
SI2297152T1 (sl) 2015-02-27
US20110166150A1 (en) 2011-07-07
PL2297152T3 (pl) 2015-04-30
AU2009235440A1 (en) 2009-10-15
CY1115961T1 (el) 2017-01-25
EP2297152B1 (en) 2014-11-12
ZA201007120B (en) 2011-11-30
PE20091839A1 (es) 2010-01-07
BRPI0911678B8 (pt) 2021-05-25
RS53732B1 (en) 2015-06-30
US8309553B2 (en) 2012-11-13
MX2010011152A (es) 2010-12-21
EP2297152A1 (en) 2011-03-23
WO2009124996A1 (en) 2009-10-15
GB0806652D0 (en) 2008-05-14
IL208597A0 (en) 2010-12-30
BRPI0911678A2 (pt) 2015-10-13
JP2014205688A (ja) 2014-10-30
AR071311A1 (es) 2010-06-09
CN102066376A (zh) 2011-05-18
AU2009235440B2 (en) 2012-06-14
HRP20141196T1 (hr) 2015-02-13
JP5875863B2 (ja) 2016-03-02

Similar Documents

Publication Publication Date Title
UY31758A (es) Forma cristalina anhidra de maleato de orvepitant
MX2010004576A (es) Derivados de pirimidina novedosos.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
WO2010030598A3 (en) Pharmaceutical formulations comprising pemetrexed
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
IL189929A0 (en) Novel dosage formulation
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
UY33124A (es) Agentes y epítopos enlazados a wise
TW200942524A (en) Novel aminomethyl benzene derivatives
UY31922A (es) Compuestos
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
IL218517A0 (en) Orthopedic plates for use in the midfoot
IL209304A0 (en) Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
NI201000212A (es) Dronedarona para la prevención de la cardioversión.
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2008001014A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de prampipexol.
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
ECSP109874A (es) Nuevos compuestos 892
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
ITPD20060092A1 (it) Prodotto cosmetico o farmaceutico per uso topico
GB0615105D0 (en) Novel compounds

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181025